Shots:
- UCB has reported the (BE BOLD) trial data assessing Bimzelx(bimekizumab-bkzx) vs Skyrizi(risankizumab-rzaa) in 553 adults living with active psoriatic arthritis (PsA)
- Trial met its 1EP, with 49.1% pts achieving ACR50 at Wk. 16 vs 38.4%. The first ranked 2EP, MDA was numerically higher at Wk. 16 (43% vs 39.9%), but did not reach statistical significance, halting sequential testing, while subsequent 2EPs descriptively favored Bimzelx
- Pts achieved simultaneous ACR50+PASI100 at Wk. 16 (33.5% vs 24.4%) & ACR50 at Wk. 4 (19.9% vs 7.2%). Among exploratory EPs, PASI100 at Wk. 16 was achieved by 53.4% vs 46.6%, while DAPSA LDA+REM was reached by 65.3% vs 54.7%; data to be presented at EULAR’26
Ref: PRnewswire | Image: UCB | Press Release
Related News: UCB to Acquire Candid Therapeutics for ~$2.2B
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
